Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

RP23-61E13.2 Inhibitors

RP23-61E13.2 inhibitors represent a chemical class designed to interact with a specific biological pathway by binding to a molecular target identified by the genetic locus RP23-61E13.2. This target is typically a protein or enzyme encoded by the corresponding gene, and the inhibitors are formulated to modulate the activity of this protein. Through this interaction, the inhibitors can affect the function of the protein, leading to alterations in the associated biological processes. The chemical structures within this class are characterized by their ability to fit into the active site or another relevant binding region of the protein, which is usually shaped to accommodate certain molecules through a highly specific lock-and-key mechanism. The design of RP23-61E13.2 inhibitors takes into account the size, shape, and electronic properties of the target site, ensuring that they are complementary and capable of forming stable interactions, often through non-covalent bonds such as hydrogen bonds, ionic interactions, and hydrophobic effects.

The development and refinement of RP23-61E13.2 inhibitors involve a rigorous process of chemical synthesis and structure-activity relationship (SAR) studies. These studies help in understanding how different chemical groups and molecular architectures influence the binding affinity and selectivity of the inhibitors towards their target. A high degree of selectivity is crucial for the efficacy of the inhibitors in modulating the activity of the target protein without affecting other proteins with similar structures. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are often employed to gain insights into the molecular interactions at play. The physicochemical properties, such as solubility, stability, and permeability, are also optimized to ensure that the inhibitors maintain their integrity and effectiveness under physiological conditions. The inhibitors in this class are the result of a convergence of various scientific disciplines, including medicinal chemistry, biochemistry, and molecular biology, which collectively contribute to the design and optimization of these molecules.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Gefitinib is an EGFR inhibitor that can indirectly inhibit RP23-61E13.2 by blocking the EGFR tyrosine kinase activity, which may be upstream in signaling pathways involving RP23-61E13.2.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin is an mTOR inhibitor that can disrupt the mTOR signaling pathway. Since mTOR can regulate various proteins and processes, including those potentially involving RP23-61E13.2, inhibition can lead to reduced function of RP23-61E13.2.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is a PI3K inhibitor that can prevent the phosphorylation and activation of AKT, which may have downstream effects leading to the inhibition of RP23-61E13.2.

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

Palbociclib is a CDK4/6 inhibitor that can halt cell cycle progression, potentially affecting the activity of RP23-61E13.2 if its function is related to cell cycle control.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

Trametinib is a MEK inhibitor that may indirectly inhibit RP23-61E13.2 by interfering with the MAPK/ERK signaling pathway which could affect proteins regulated by this pathway.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Sorafenib is a kinase inhibitor with targets that include VEGFR and PDGFR, potentially influencing angiogenesis and cell survival pathways that RP23-61E13.2 could be involved in.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 is a selective inhibitor of MEK1/2 which can alter the MAPK/ERK pathway, possibly affecting the functional activity of RP23-61E13.2 if it is a downstream effector.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib is a proteasome inhibitor that can affect the degradation of proteins, which might influence the stability and function of RP23-61E13.2.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Imatinib is a tyrosine kinase inhibitor that can affect the BCR-ABL signaling pathway and potentially other kinases that could indirectly influence the activity of RP23-61E13.2.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a JNK inhibitor that may prevent the activation of transcription factors and other proteins that are involved in pathways where RP23-61E13.2 has a role.